NASDAQ$REGN
Regeneron Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Reported strong financial results driven by growth in revenues and net income.
Regeneron reported a strong third quarter in 2021, with total revenues increasing by 51% to $3.45 billion compared to the third quarter of 2020. GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37. The company saw growth in EYLEA U.S. net sales and Dupixent global net sales.
- Third quarter revenues increased 51% to $3.45 billion versus third quarter 2020, including $804 million attributable to REGEN-COV.
- EYLEA U.S. net sales increased 12% versus third quarter 2020 to $1.47 billion.
- Dupixent global net sales increased 55% to $1.66 billion versus third quarter 2020.
- GAAP diluted EPS was $14.33 and non-GAAP diluted EPS was $15.37.
Headline financials
Revenue & EPS history
Regeneron · Revenue · Quarterly
$3.45B
Revenue by segment
Regeneron · $3.41B total across 6 segments · Q1 2023
- Net product sales$1.67B+1.8%48.9%
- EYLEA U.S.$1.43B—42.1%
- Other revenue$116M+23.4%3.4%
- Libtayo U.S.$110M—3.2%
- Libtayo ROW$67M—2.0%
- Evkeeza U.S.$15M—0.4%
Forward guidance
Regeneron's full year 2021 financial guidance includes estimates for R&D, SG&A, gross margin on net product sales, COCM, other operating expense, capital expenditures, and effective tax rate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.5%
Avg return
Earnings day
+1.2%
Avg return
5 days after
+3.1%
Avg return
30 days after
54%
35 / 65 earnings
Positive
+11.7%
Q2 2012
Best reaction
-8.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -3.1% | -16.0% | |
| Q4 2025 | -0.5% | +3.4% | +4.3% | |
| Q3 2025 | +11.1% | +11.4% | +34.1% | |
| Q2 2025 | +2.5% | +1.8% | +6.5% | |
| Q1 2025 | -6.9% | -0.9% | -0.9% | |
| Q4 2024 | +4.5% | +6.5% | +4.7% | |
| Q3 2024 | -8.6% | -10.1% | -18.7% | |
| Q2 2024 | +0.3% | -1.2% | +9.8% | |
| Q1 2024 | +5.9% | +7.4% | +8.5% | |
| Q4 2023 | -2.2% | -2.0% | +2.6% | |
| Q3 2023 | +3.2% | +5.0% | +3.0% | |
| Q2 2023 | +4.7% | +6.6% | +13.6% | |
| Q1 2023 | -5.1% | -6.0% | -7.9% | |
| Q4 2022 | +3.9% | -0.2% | +3.7% | |
| Q3 2022 | -0.0% | +1.5% | +3.5% | |
| Q2 2022 | +7.0% | +9.7% | +1.0% | |
| Q1 2022 | -3.2% | -9.2% | -4.6% | |
| Q4 2021 | +0.3% | -0.1% | -0.0% | |
| Q3 2021 | -6.2% | -5.5% | -2.6% | |
| Q2 2021 | +5.1% | +5.9% | +17.0% | |
| Q1 2021 | +3.0% | +3.9% | +6.1% | |
| Q4 2020 | -0.8% | -1.5% | -7.5% | |
| Q3 2020 | -1.6% | -4.8% | -16.1% | |
| Q2 2020 | -4.2% | -6.2% | -10.5% | |
| Q1 2020 | +2.2% | +4.0% | +10.5% | |
| Q4 2019 | +2.6% | +6.6% | +32.9% | |
| Q3 2019 | +4.3% | +9.9% | +18.4% | |
| Q2 2019 | +0.9% | +1.8% | -3.4% | |
| Q1 2019 | -4.4% | -9.1% | -13.0% | |
| Q4 2018 | -3.5% | -3.0% | -4.4% | |
| Q3 2018 | +2.6% | +0.5% | +7.5% | |
| Q2 2018 | +6.4% | +5.5% | +9.6% | |
| Q1 2018 | -1.7% | -3.5% | +3.6% | |
| Q4 2017 | +0.5% | -3.0% | +2.1% | |
| Q3 2017 | +0.5% | -2.7% | -5.8% | |
| Q2 2017 | -1.7% | -1.5% | +5.7% | |
| Q1 2017 | +5.4% | +5.0% | +18.0% | |
| Q4 2016 | +1.9% | +6.6% | +9.9% | |
| Q3 2016 | +8.7% | +24.5% | +10.9% | |
| Q2 2016 | -4.2% | -5.0% | -11.9% | |
| Q1 2016 | +2.6% | — | — | |
| Q4 2015 | -5.9% | — | — | |
| Q3 2015 | -2.4% | — | — | |
| Q2 2015 | +6.9% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -6.8% | — | — | |
| Q2 2014 | +4.7% | — | — | |
| Q1 2014 | -2.5% | — | — | |
| Q4 2013 | +5.4% | — | — | |
| Q3 2013 | +2.3% | — | — | |
| Q2 2013 | -6.6% | — | — | |
| Q1 2013 | +5.7% | — | — | |
| Q4 2012 | -3.2% | — | — | |
| Q3 2012 | -8.3% | — | — | |
| Q2 2012 | +11.7% | — | — | |
| Q1 2012 | +1.5% | — | — | |
| Q4 2011 | -3.6% | — | — | |
| Q3 2011 | -3.5% | — | — | |
| Q2 2011 | +0.8% | — | — | |
| Q1 2011 | +1.3% | — | — | |
| Q4 2010 | -0.6% | — | — | |
| Q3 2010 | -3.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q1 2010 | +3.7% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro